Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

Chronic myeloid leukemia (CML) with T315I mutation has been reported to have poor prognosis. We analyzed 27 patients with T315I, including 20 who developed T315I after imatinib failure (representing 11% of 186 patients with imatinib failure), and 7 of 23 who developed new mutations after second tyro...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Jabbour, Elias, Kantarjian, Hagop, Jones, Dan, Breeden, Megan, Garcia-Manero, Guillermo, O'Brien, Susan, Ravandi, Farhad, Borthakur, Gautam, Cortes, Jorge
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2008
Teme:
Clinical Trials and Observations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081375/
https://ncbi.nlm.nih.gov/pubmed/18403620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-11-123950
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki